AmyDTierstenMD

Associate Professor, Medicine, New York University School of Medicine

Overview of Dr. Tiersten

Dr. Amy Tiersten is an oncologist in New York, NY and is affiliated with The Mount Sinai Hospital. She received her medical degree from New York University Grossman School of Medicine and has been in practice 27 years. Dr. Tiersten accepts several types of health insurance, listed below. She is one of 191 doctors at The Mount Sinai Hospital who specialize in Oncology. She has more than 60 publications and over 500 citings.

Office
1 Gustave L Levy Pl
New York, NY 10029
Book by Phone+1(541) 527-7341

Fax+1 646-537-8610
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1990 - 1993
New York University School of MedicineClass of 1990

Certifications & Licensure

NY State Medical License 1991 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 1997 Jan 01
Unknown status
Phase 1, Phase 2
Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix Start of enrollment: 1997 Jan 01
Completed
Phase 2
Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer Start of enrollment: 1997 Feb 01
Unknown status
Phase 2
Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 1998 May 01
Unknown status
Phase 2
S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Start of enrollment: 2001 Mar 01
Completed
Phase 2
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2003 Apr 01
Terminated
Phase 2
Oxaliplatin and Topotecan in Advance Ovarian Cancer Start of enrollment: 2006 Jan 01
Terminated
Phase 2
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Start of enrollment: 2006 Jun 01
Completed
Phase 1
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer Start of enrollment: 2010 Mar 01
Completed
Phase 2
RAD001 Plus Carboplatin in Breast Cancer Patients Start of enrollment: 2010 Jun 01
Completed
Phase 2
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Comparison of Nutrition Education Alone or With Acupuncture for Weight Loss in Breast Cancer Patients Post-Chemotherapy Start of enrollment: 2014 Sep 01
Completed
Not Applicable
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer Start of enrollment: 2015 Dec 16
Active, not recruiting
Phase 2
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer Start of enrollment: 2016 Mar 01
Active, not recruiting
Phase 2
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. Start of enrollment: 2016 Oct 01
Terminated
Phase 1
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Start of enrollment: 2017 Dec 20
Active, not recruiting
Phase 1, Phase 2
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer Start of enrollment: 2018 May 17
Completed
Phase 1
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer Start of enrollment: 2020 Oct 01
Withdrawn
Phase 2
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer Start of enrollment: 2024 Mar 01
Not yet recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report.
Camille M Powers, Hannah Verma, Jeremy Orloff, Austin J Piontkowski, Angela Lamb, Amy Tiersten, Nicholas Gulati> ;The Journal of Dermatological Treatment. 2024 Dec 1
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or...
Cynthia X Ma, Vera J Suman, Souzan Sanati, Kiran Vij, Meenakshi Anurag, A Marilyn Leitch, Gary W Unzeitig, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard...> ;JAMA Oncology. 2024 Mar 1
Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer.
Meng Ru, Julie Fasano, Paula Klein, Theresa Shao, Chrystal A Landry, Julia Blanter, Aarti Bhardwaj, Amy Tiersten> ;Oncology. 2024 Jan 1
Outcomes in Premenopausal Patients with HR+/HER2- Breast Cancer and Lymph Node Micrometastasis Based on the 21-Gene Recurrence Score.
Nadeem Bilani, Rima Patel, Fionnuala Crowley, Amy Tiersten> ;The Oncologist. 2023 Dec 11
10 citations
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Hum...
Kevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, Prabhjot S Mundi, Elizabeth Sakach, Claire Sathe, Heejoon Ahn, Meghna S Trivedi, Yelena Novik, Amy Tiersten, Geor...> ;Journal of Clinical Oncology. 2023 Aug 20
17 citations
An emerging generation of endocrine therapies in breast cancer: a clinical perspective.
Rima Patel, Paula Klein, Amy Tiersten, Joseph A Sparano> ;NPJ Breast Cancer. 2023 Apr 5
3 citations
Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer.
Rima Patel, Malin Hovstadius, Melanie W Kier, Erin L Moshier, Brittney S Zimmerman, Krystal Cascetta, Shabnam Jaffer, Joseph A Sparano, Amy Tiersten> ;Cancer. 2022 Oct 1
3 citations
Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer.
Rima Patel, Zhiqiang Li, Brittney S Zimmerman, Marc Y Fink, Jason D Wells, Xiang Zhou, Kristin Ayers, Arielle Redfern, Scott Newman, Eric Schadt, William K Oh, Rong Ch...> ;Breast Cancer Research and Treatment. 2022 Apr 1
6 citations
Impact of the COVID-19 Pandemic on Cancer Care and Quality of Life for Patients With Breast and Gynecologic Malignancies: A Single-Center Survey-Based Study.
Natalie F Berger, Brittney S Zimmerman, Danielle Seidman, Krystal P Cascetta, Erin Moshier, Michelle Nezolosky, Kara Trlica, Alisa Ryncarz, Caitlin Keeton, Amy Tiersten> ;Journal of Patient Experience. 2022 Jan 1
1 citations
Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Natalie F Berger, Brittney S Zimmerman, Serena Tharakan, Kelly I Suchman, Krystal Pauline Cascetta, Julia Blanter, Erin Moshier, Meng Ru, Shabnam Jaffer, Amy Tiersten> ;Oncology. 2021 Jan 1
13 citations
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
Matthew R Kearney, Lauren Franks, Shing Lee, Amy Tiersten, Della F. Makower, Tessa Cigler, Prabhjot S. Mundi, Dow Chung Chi, Anupama Goel, Pam Klein, Eleni Andreopoulo...> ;Breast Cancer Research and Treatment. 2021 Jun 24
4 citations
Association of Insulin Resistance and Higher Oncotype DX™ Recurrence Score.
Nicole T. Gordon, J. Jaime Alberty-Oller, Kezhen Fei, Giampaolo Greco, Emily J. Gallagher, Derek LeRoith, Sheldon Feldman, Bridgid Killilea, Susan K. Boolbol, Lydia Ch...> ;Annals of Surgical Oncology. 2021 Apr 3
6 citations
Prognostic Factors and Survival Outcomes among Patients with Breast Cancer and Brain Metastases at Diagnosis: A National Cancer Database Analysis
Brittney S Zimmerman, Danielle Seidman, Krystal Pauline Cascetta, Meng Ru, Erin Moshier, Amy Tiersten> ;Oncology. 2021 Mar 2
46 citations
Patient perception of telehealth services for breast and gynecologic oncology care during the covid-19 pandemic: A single center survey-based study
Brittney S Zimmerman, Danielle Seidman, Natalie Berger, Krystal Pauline Cascetta, Michelle Nezolosky, Kara Trlica, Alisa Ryncarz, Caitlin Keeton, Erin Moshier, Amy Tie...> ;Journal of Breast Cancer. 2020 Oct 19
1 citations
Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients.
Serena Tharakan, Brittney S Zimmerman, Meng Ru, Julia Blanter, Krystal Pauline Cascetta, Amy Tiersten> ;Oncology. 2020 Mar 17
2 citations
Novel breast cancer treatment leads to hyperglycaemia
I.R. Bass, Amy Tiersten, Kara Trlica, Alisa Ryncarz, B. Adler, Emily J. Gallagher> ;Diabetic Medicine. 2020 Feb 24
18 citations
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast ...
Bhavana Pothuri, Allison L. Brodsky, Joseph A. Sparano, Stephanie V. Blank, Mimi Kim, Dawn L. Hershman, Amy Tiersten, Brian F. Kiesel, Jan H. Beumer, Leonard Liebes, F...> ;Cancer Chemotherapy and Pharmacology. 2020 Feb 13
6 citations
BRCA Mutation Association with Recurrence Score and Discordance in a Large Oncotype Database.
Julia Blanter, Brittney S Zimmerman, Serena Tharakan, Meng Ru, Krystal Pauline Cascetta, Amy Tiersten> ;Oncology. 2020 Jan 21
38 citations
Physical Symptom Burden and Its Association With Distress, Anxiety, and Depression in Breast Cancer.
Daniel C. McFarland, Kelly M. Shaffer, Amy Tiersten, Jimmie C. Holland> ;Psychosomatics. 2018 Sep 1
38 citations
Prevalence of physical problems detected by the distress thermometer and problem list in patients with breast cancer.
Daniel C. McFarland, Kelly M. Shaffer, Amy Tiersten, Jimmie C. Holland> ;Psycho-Oncology. 2018 Feb 1
6 citations
Molecular Imaging of Apoptosis in Cancer Therapy-Related Cardiac Dysfunction Before LVEF Reduction
Takehiro Nakahara, Artiom Petrov, Takashi Tanimoto, Farhan Chaudhry, Navneet Narula, Surya V. Seshan, Jeffrey A. Mattis, Koon Y. Pak, Gagan Sahni, Aarti Sonia Bhardwaj...> ;JACC. Cardiovascular Imaging. 2018 Mar 2
24 citations
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
Fernanda Musa, Bhavana Pothuri, Stephanie V. Blank, Huichung T. Ling, James L. Speyer, John P. Curtin, Leslie R. Boyd, Xiaochun Li, Judith D. Goldberg, Franco M. Muggi...> ;Gynecologic Oncology. 2017 Feb 1
13 citations
Palliation of Ulcerative Breast Lesions with Radiation
Prashant Vempati, Miriam A. Knoll, Kavita V. Dharmarajan, S Green, Amy Tiersten, Richard L. Bakst> ;Anticancer Research. 2016 Sep 1
8 citations
Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years
Daniel C. McFarland, Jessica Naikan, Mariya Rozenblit, John Mandeli, Ira J. Bleiweiss, Amy Tiersten> ;Journal of Oncology. 2016 Jun 13
16 citations
Early Childhood Adversity and its Associations With Anxiety, Depression, and Distress in Women With Breast Cancer
Daniel C. McFarland, Charissa Andreotti, Kirk A Harris, John Mandeli, Amy Tiersten, Jimmie C. Holland> ;Psychosomatics. 2016 Mar 1
Join now to see all

Press Mentions

Breast Cancer Treatments Propel Many Women into ‘Rapid, Dramatic’ Medical MenopauseOctober 22nd, 2021
PARP Inhibitor Staves off Recurrence in Early BRCA-Mutant Breast CancerJune 16th, 2021
Lynparza Can Cure Breast Cancer at an Early StageJune 7th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

The Mount Sinai HospitalNew York, New York

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Healthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment